Drugs to treat cancer, high blood pressure, and seizures experienced large price spikes in 2015, costing taxpayers millions of dollars in added Medicare spending, according to new data released by the federal Centers for Medicare and Medicaid Services.

The data show which drugs cost taxpayers the most money overall and pinpoint which medications experienced the biggest price increases. For the first time this year, CMS released five years of pricing information on more than 5,000 drugs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
    • Paul, no clue about Zestril which has been generic for over a decade if I’m not mistaken– how generic manufacturers can get away with large price increases is a mystery to me unless they are such specialty drugs that they are a sole manufacturer. Antihypertensives are the opposite of specialty drugs.
      Regarding Cozaar, this went off patent about 5 years ago and this is 5 year data. It is a common strategy for a pharma company to take major price hikes in the last year of a patent. Payers know the drug is nearing patent expiration so they wait rather than resist, knowing they will control the costs of a drug in the near term. Trying to restrict a drug– especially when its one used by millions of patients and about to go off patent just doesn’t make financial sense for Payers, and the pharma companies know it.

  • For generic drugs, I give all my patients information about Blink Health – where a quick search shows pricing for Cozaar at $6.27 for a one month supply.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy